Area 5

Hemotherapy - hemostasis

Team leader

Strategic objectives

  1. Study of the basic mechanisms regulating blood cell function and of the interactions between such cells, with the vascular wall, and with other cells.
  2. Evaluation of congenital and acquired defects in hemostasis and their pharmacological and/or transfusional correction.
  3. Laboratory characterization of bleeding and thrombotic phenotypes and genotypes
  4. Analysis of the efficacy and safety of new strategies for sparing blood component transfusions.
  5. Characterization of animal models of hemostasis, preferentially in mice.

Main lines of research

  1. Study of the mechanisms involved in the development of bleeding and thrombotic disorders. Proteomic study for determining the changes in the vascular system and in the different blood cells in thrombotic and bleeding disorders.
  2. Evaluation of the physiological and pathological implications of circulating and/or intraplatelet tissue factor in atherothrombosis.
  3. Characterization of endothelial dysfunction as a common factor in the development of complications associated with multiple diseases. A physiological, biochemical and proteomic approach.
  4. New strategies for the treatment of combined humoral immunity in therapeutic apheresis.
  5. Evaluation of the participation of serotoninergic and purinergic mechanisms in platelet function. Study of the antithrombotic potential of pharmacological inhibitors.
  6. Role of the phenotype/genotype of fibrinolysis and its repercussions upon global or specific functional tests in hemorrhagic and thrombotic pathology.
  7. Study of the GAS6 vitamin K-dependent protein in hemostasis and the vascular wall, using knockout mice for this gene.
  8. Evaluation of the potencial of clotting factor concentrates to reverse the anticoagulant action of the new oral antithrombotic agents